Can a hyperopic patient be fitted with the EVO Visian Implantable Collamer Lens (myopic model), and does this require a peripheral iridotomy?

EVO ICL Does Not Require Peripheral Iridotomy for Any Refractive Indication

The EVO Visian ICL (with central port design) eliminates the need for peripheral iridotomy regardless of the refractive error being corrected, including hyperopia. However, the current FDA-approved EVO ICL models are specifically indicated for myopia correction only (up to -20.00 D), not hyperopia 1.

Key Distinction: Indication vs. Iridotomy Requirement

Your question conflates two separate issues:

1. FDA Approval for Hyperopia

• The EVO/EVO+ ICL is FDA-approved exclusively for myopia correction (with or without astigmatism up to 4.00 D) 1
• Hyperopic patients cannot currently receive FDA-approved EVO ICL because no hyperopic model exists in the U.S. market 1
• Phakic IOLs for hyperopia correction exist in concept but are not part of the current EVO ICL product line 1

2. Iridotomy Requirement (Separate from Indication)

• The EVO ICL's central aqueous port (0.36 mm diameter) eliminates the need for peripheral iridotomy by preventing pupillary block through continuous aqueous humor flow 1, 2
• This design feature applies to all EVO ICL models regardless of the refractive error being treated 2, 3
• In the FDA clinical trial of 629 eyes, zero eyes required peripheral iridotomy or iridectomy, and no cases of pupillary block occurred over 3 years 4, 3

Comparison with Older ICL Models

Older Models (V4, V4b, V4c without central port)

• Required mandatory peripheral iridotomy performed 7-14 days preoperatively using Nd:YAG laser 1
• Iridotomies were placed superiorly (0.2-0.5 mm size) to prevent pupillary block 1
• Pitfall: Iridotomies straddling the lid margin caused postoperative glare and ghosting 1, 2

Current EVO Models (V5 with CentraFLOW)

• No iridotomy needed due to central port design 2, 4, 3
• Maintains physiologic aqueous flow from posterior to anterior chamber 4, 3, 5
• Reduced incidence of anterior subcapsular cataract (only 0.16% at 2 years vs. 1.0-2.3% with older models) 1, 4

Clinical Algorithm for Phakic IOL Selection

For myopic patients (-3.00 to -20.00 D with ≤4.00 D astigmatism):

• First-line: EVO/EVO+ ICL (no iridotomy required) 1, 4, 3
• Verify adequate vault (mean 528-557 μm) at 3 months post-op 5
• Monitor endothelial cell density (expect 6.7% loss at 3 years) 4

For hyperopic patients:

• EVO ICL is not an option (no FDA-approved hyperopic model) 1
• Consider alternative phakic IOLs (e.g., iris-fixated Artisan/Verisyse) which do require peripheral iridotomy 1
• Alternative: Refractive lens exchange or corneal procedures 1

Safety Profile of EVO ICL

The 3-year FDA trial demonstrated exceptional safety 4:

• Zero cases of pupillary block requiring iridotomy 4, 3
• Zero cases of elevated IOP from angle narrowing or pigment dispersion 4, 3
• Only 2 eyes (0.32%) required lens exchange for high vault 4
• Safety index of 1.25 (48.9% gained ≥1 line of CDVA) 4

Common Pitfall to Avoid

Do not confuse the iridotomy requirement with refractive indication. The central port design eliminates iridotomy needs for all potential EVO ICL applications 2, but this does not mean hyperopic patients can receive the lens—they simply cannot because no hyperopic EVO model exists in the U.S. 1.